Autres langues Sensorion

Actions

ALSEN

FR001401A9Z0

Recherche biotechnologique et médicale

Temps réel Euronext Paris 15:22:48 30/09/2026			Varia. 5j.	Varia. 1 janv.
7,358 ^EUR	-6,10%		-6,27%	-56,33%

18/09	Sensorion annonce les modalités d'inscription pour la journée dédiée au programme SENS-601 et fait le point sur son portefeuille de produits SENS-601 et SENS-401	CI
16/09	Bourse : Renault investit au Brésil, Veolia muscle son actionnariat salarié, 2CRSi tente de rassurer

Autres langues

23/09	Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2026
23/09	Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
18/09	Sensorion Announces Registration And Connection Details For SENS-601 Program Day And Provides Updates On SENS-601 And SENS-401 Product Pipeline
18/09	Sensorion Announces Connection Details for its SENS-601 Program Day on September 22, 2026
16/09	Sensorion Confidentially Files Draft Registration Statement for Potential US IPO
16/09	Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering
15/09	Sensorion Completes 50-to-1 Reverse Stock Split
15/09	Sensorion Announces the Completion of Its Reverse Share Split
03/09	Sensorion Receives Clinical Trial Authorization in France for SENS-601 Gene Therapy for Gjb2-Related Hearing Loss
03/09	Sensorion Gets Go-ahead in France for Trial of Lead Gene Therapy Candidate for Hearing Loss
03/09	Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
29/07	Sensorion Announces a Reverse Share Split of its Shares
10/06	Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
10/06	Sensorion Applies for Clinical Trial in Canada, France for SENS-601
10/06	Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
18/05	French Biotech Company Sensorion Names New CEO
18/05	Sensorion : Inside Information / Other news releases
18/05	Sensorion Appoints Fred Chereau as Chief Executive Officer
18/05	Sensorion SA Announces Chief Executive Officer Changes
18/05	Sensorion SA Announces Resignation of Géraldine Honnet as Chief Medical Officer
13/05	Sensorion : Inside Information / Other news releases
13/05	Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
05/05	Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
01/05	Certain Ordinary Shares of Sensorion SA are subject to a Lock-Up Agreement Ending on 1-MAY-2026.
22/04	Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 11, 2026